tradingkey.logo
tradingkey.logo
Search

Coya Therapeutics Inc

COYA
Add to Watchlist
4.790USD
0.0000.00%
Close 08-14 16:00ETQuotes delayed by 15 min
112.36MMarket Cap
LossP/E TTM

Forecast

Currency: USD Updated: 2026-08-14
Previous score
8.33
Change
0
The current earnings forecast score of Coya Therapeutics Inc is 8.33, ranking 139 out of 387 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 18.00 and a low of 14.00.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
15.750
Target Price
+228.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Coya Therapeutics Inc
COYA
6
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Coya Therapeutics Inc's expected revenue for the next quarter?

Coya Therapeutics Inc's expected revenue is 100.00K.

What is Coya Therapeutics Inc's price target?

Analysts forecast that Coya Therapeutics Inc's price target is USD 16.00, with the highest forecast at USD 18.00 and the lowest forecast at USD 14.00.

How have Coya Therapeutics IncCOYA's recent earnings per share performed?

The market expectation was USD -0.28, while Coya Therapeutics IncCOYA's earnings per share (EPS) for the previous quarter was USD -0.32. EPS for the next quarter is expected at USD -0.36.

What is the analyst rating for Coya Therapeutics Inc?

Based on the ratings of Coya Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.